Condition: Pancreatic Ductal Adenocarcinoma · Sponsor: Baylor College of Medicine
Abbreviated Title: Neoadjuvant FOLFIRINOX combined with Pembrolizumab followed by surgery for patients with resectable pancreatic cancer Trial Phase: Phase II Clinical Indication: Pancreatic ductal adenocarcinoma; Adenocarcinoma; AJCC I, II, or III; 1st Line neoadjuvant Trial Type: Interventional prospective Type of control: Historical Route of administration: IV Treatment Groups: Neoadjuvant FOLFIRINOX combined with Pembrolizumab followed by surgery for patients with resectable pancreatic cancer Number of trial participants: 30 Estimated enrollment period: 24 months Estimated duration of trial: 3.5 Years Duration of Participation:16 months Estimated average length of treatment per patient: 16 months
This description comes directly from the study's public registry record.
Ernest R. Camp, M.D., M.S.C.R., F.A.C.S. · 713-798-7828 · Ramsay.camp@bcm.edu
Benjamin Musher, M.D. · 713-798-4292 · blmusher@bcm.edu
Always discuss trial participation with your own doctor first.
| Baylor College of Medicine | Houston, Texas, United States | Recruiting |
| Baylor St. Luke's Medical Center (BSLMC). | Houston, Texas, United States | Recruiting |
| Houston Methodist Hospital | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05132504